In yesterday’s Wall Street session, Amarin Corporation plc (NASDAQ:AMRN) shares traded at $1.17, up 2.63% from the previous session.
5 analysts cover Amarin Corporation plc (NASDAQ:AMRN), according to research data. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $1.50, we find $2.00. Given the previous closing price of $1.14, this indicates a potential upside of 75.44 percent. AMRN stock price is now -5.98% away from the 50-day moving average and -16.04% away from the 200-day moving average. The market capitalization of the company currently stands at $465.23M.
The stock has received a hold rating from 2 analysts and a buy rating from 2. Brokers who have rated the stock have averaged $2.70 as their price target over the next twelve months.
With the price target enhanced from $1.30 to $3, Jefferies Upgraded its rating from Hold to Buy for Amarin Corporation plc (NASDAQ: AMRN).
Insiders disposed of 282,962 shares of company stock worth roughly $0.33 million over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AMRN stock. A new stake in Amarin Corporation plc shares was purchased by TANG CAPITAL MANAGEMENT LLC during the first quarter worth $6,318,000. GRATUS CAPITAL LLC invested $2,122,000 in shares of AMRN during the first quarter. In the first quarter, SIMPLICITY SOLUTIONS, LLC acquired a new stake in Amarin Corporation plc valued at approximately $550,000. ARTIA GLOBAL PARTNERS LP acquired a new stake in AMRN for approximately $300,000. MARSHALL WACE, LLP purchased a new stake in AMRN valued at around $258,000 in the second quarter. In total, there are 239 active investors with 32.70% ownership of the company’s stock.
On Monday morning Amarin Corporation plc (NASDAQ: AMRN) stock kicked off with the opening price of $1.1400. During the past 12 months, Amarin Corporation plc has had a low of $1.04 and a high of $2.23. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.80, and a quick ratio of 1.90. The fifty day moving average price for AMRN is $1.2426 and a two-hundred day moving average price translates $1.3936 for the stock.
The latest earnings results from Amarin Corporation plc (NASDAQ: AMRN) was released for Mar, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at -$0.04, missing analysts’ expectations of -$0.03 by -0.01. This compares to -$0.08 EPS in the same period last year. The net profit margin was -25.20% and return on equity was -15.50% for AMRN. The company reported revenue of $85.97 million for the quarter, compared to $94.63 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -9.15 percent. For the current quarter, analysts expect AMRN to generate $79.58M in revenue.
Amarin Corporation plc(AMRN) Company Profile
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
